Nonallergic rhinitis (NAR) — long lumped in with allergic rhinitis or dismissed as a minor nuisance — is getting a scientific makeover. Affecting an estimated 20%–70% of adults and rising alongside urbanization, NAR is now understood as a syndrome of neurogenic hyperreactivity rather than simply an inflammatory condition. Experts presented updated frameworks at the Rhinoforum 2026 conference, emphasizing that the nervous system — not just immune cells — is a central driver of symptoms.

The condition spans multiple subtypes, from eosinophilic (NARES) and drug-induced forms to idiopathic rhinopathy, the most common type (50%+ of cases). In idiopathic rhinopathy, overactive nerve channels — particularly TRPV1 receptors in trigeminal sensory fibers — respond to nonspecific triggers like cold air, fragrances, and emotions. Notably, the outdated term "vasomotor rhinitis" has been officially replaced by "nonallergic rhinopathy" to better reflect this neurogenic mechanism.

Key Takeaways:

• NAR is associated with a 2.71x increased risk of asthma (vs. 3.53x for allergic rhinitis)
• Idiopathic rhinitis accounts for ~40–50% of NAR cases; local allergic rhinitis ("entopy") accounts for 10–45%
• Neuro-targeted treatments — including capsaicin and posterior nasal nerve ablation (radiofrequency, cryotherapy) — are emerging options for refractory cases

Why it matters: Reframing NAR as a neurogenic disorder could transform how clinicians diagnose and treat millions of patients who don't respond to standard anti-inflammatory therapies.